Use of biosimilars in inflammatory bowel disease: statements of the Italian group for inflammatory bowel disease

V Annese, M Vecchi, F Bossa, E Calabrese… - Digestive and Liver …, 2014 - Elsevier
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …
被引用次数：53 相关文章

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

V Annese, M Vecchi - … liver disease: official journal of the …, 2014 - pubmed.ncbi.nlm.nih.gov
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

[引用][C] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.

V Annese, M Vecchi, F Castiglione… - DIGESTIVE AND LIVER …, 2014 - iris.unina.it
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for
Inflammatory Bowel Disease. IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo …

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

V Annese, M Vecchi, F Bossa… - Digestive and Liver …, 2014 - dldjournalonline.com
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

[引用][C] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

MV V Annese, IG Bossa, E Calabrese… - … AND LIVER DISEASE, 2014 - iris.hunimed.eu
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for
Inflammatory Bowel Disease IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore …

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

V Annese, M Vecchi, F Bossa, E Calabrese… - … AND LIVER DISEASE, 2014 - ricerca.uniba.it
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

[引用][C] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

MV V Annese, IG Bossa, E Calabrese… - DIGESTIVE AND LIVER …, 2014 - iris.unisr.it
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for
Inflammatory Bowel Disease IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore …

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.

V Annese, M Vecchi - Digestive and Liver Disease: Official Journal …, 2014 - europepmc.org
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

V Annese, M Vecchi, F Bossa… - … AND LIVER DISEASE, 2014 - publicatt.unicatt.it
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

AV Vecchi M, F Bossa, E Calabrese… - … AND LIVER DISEASE, 2014 - iris.uniroma1.it
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …